Binding of staphylococcal cell surface polysaccharide to human fibrinogen. 1990

T Ohtomo, and T Kobayashi, and Y Ohshima, and Y Usui, and M Suganuma, and K Yoshida
Department of Microbiology, St. Marianna University School of Medicine, Kawasaki, Japan.

The interaction between the binding site of a polysaccharide (called compact colony forming active substance (CCFAS)), obtained from the cell surface of a strain of Staphylococcus, and human fibrinogen (HF) was investigated. The CCFAS was found to bind specifically to both the B beta and gamma chains of HF at pH 7.0 and 8.0, and the A alpha chain at pH 5.0. The binding of CCFAS with fibrinogen fragments obtained by digestion with plasmin were also investigated. Fragments with Mr of 55,000, 24,000, and 19,000 were the major bands precipitated by CCFAS at pH 7.0 and 8.0. Fragments with Mr of 85,000 and 75,000 bound to CCFAS at pH 5.0. Binding of CCFAS (7 micrograms) with fibrinogen could be inhibited by 1.2 micrograms of B beta chain and 1.5 micrograms gamma chain at alkaline pH or 6.2 micrograms of the A alpha chain at pH 5.0. CCFAS was, therefore, assumed to be specifically bonded with HF molecules, in the alkaline range at least, resulting in compact colony forming activity in serum soft agar and paracoagulation.

UI MeSH Term Description Entries
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D011135 Polysaccharides, Bacterial Polysaccharides found in bacteria and in capsules thereof. Bacterial Polysaccharides
D002462 Cell Membrane The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells. Plasma Membrane,Cytoplasmic Membrane,Cell Membranes,Cytoplasmic Membranes,Membrane, Cell,Membrane, Cytoplasmic,Membrane, Plasma,Membranes, Cell,Membranes, Cytoplasmic,Membranes, Plasma,Plasma Membranes
D005340 Fibrinogen Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products. Coagulation Factor I,Factor I,Blood Coagulation Factor I,gamma-Fibrinogen,Factor I, Coagulation,gamma Fibrinogen
D005341 Fibrinolysin A product of the lysis of plasminogen (profibrinolysin) by PLASMINOGEN activators. It is composed of two polypeptide chains, light (B) and heavy (A), with a molecular weight of 75,000. It is the major proteolytic enzyme involved in blood clot retraction or the lysis of fibrin and quickly inactivated by antiplasmins. Plasmin,Fibrogammin,Glu-Plasmin,Protease F,Thrombolysin,Glu Plasmin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006863 Hydrogen-Ion Concentration The normality of a solution with respect to HYDROGEN ions; H+. It is related to acidity measurements in most cases by pH pH,Concentration, Hydrogen-Ion,Concentrations, Hydrogen-Ion,Hydrogen Ion Concentration,Hydrogen-Ion Concentrations
D013211 Staphylococcus aureus Potentially pathogenic bacteria found in nasal membranes, skin, hair follicles, and perineum of warm-blooded animals. They may cause a wide range of infections and intoxications.

Related Publications

T Ohtomo, and T Kobayashi, and Y Ohshima, and Y Usui, and M Suganuma, and K Yoshida
September 1986, Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene. Series A, Medical microbiology, infectious diseases, virology, parasitology,
T Ohtomo, and T Kobayashi, and Y Ohshima, and Y Usui, and M Suganuma, and K Yoshida
July 1978, Experientia,
T Ohtomo, and T Kobayashi, and Y Ohshima, and Y Usui, and M Suganuma, and K Yoshida
December 1982, Biochimica et biophysica acta,
T Ohtomo, and T Kobayashi, and Y Ohshima, and Y Usui, and M Suganuma, and K Yoshida
September 2017, mBio,
T Ohtomo, and T Kobayashi, and Y Ohshima, and Y Usui, and M Suganuma, and K Yoshida
October 1986, The Journal of clinical investigation,
T Ohtomo, and T Kobayashi, and Y Ohshima, and Y Usui, and M Suganuma, and K Yoshida
February 2008, Biochemistry,
T Ohtomo, and T Kobayashi, and Y Ohshima, and Y Usui, and M Suganuma, and K Yoshida
June 2019, The FEBS journal,
T Ohtomo, and T Kobayashi, and Y Ohshima, and Y Usui, and M Suganuma, and K Yoshida
April 2001, Oral microbiology and immunology,
T Ohtomo, and T Kobayashi, and Y Ohshima, and Y Usui, and M Suganuma, and K Yoshida
March 1980, Cellular immunology,
T Ohtomo, and T Kobayashi, and Y Ohshima, and Y Usui, and M Suganuma, and K Yoshida
October 2019, Nano letters,
Copied contents to your clipboard!